摘要
目的:探讨SCN10A基因外显子区rs12632942位点多态性与结直肠癌(CRC)患者化疗奥沙利铂外周神经毒性(OXLIPN)的相关性。方法:选取2011年1月至2013年6月广州医科大学附属第二医院、南昌大学第二附属医院、广州市白云区中医医院319例接受含奥沙利铂(OXL)化疗方案的CRC患者(均为中国中南地区汉族)血液标本,常规提取DNA、PCR扩增及分析SCN10A外显子多态位点rs12632942基因型,评估OXLIPN程度。通过单因素卡方检验、Logistic多因素回归分析评估外显子多态rs12632942基因型与OXLIPN的相关性。结果:319例CRC患者rs12632942基因型:AA134例、AG156例、GG29例,rs12632942基因型频率符合哈温平衡(P>0.05)。rs12632942的AG+GG基因型与Ⅱ~Ⅳ度OXLIPN相关(P<0.01),是发生Ⅱ~Ⅳ度OXLIPN的独立危险因素(OR=2.044,95%CI=1.231~3.392,P<0.01)。结论:SCN10A基因外显子区rs12632942AG+GG基因型的CRC患者易感Ⅱ~Ⅳ度OXLIPN。
Objective:To explore the association between single nucleotide polymorphism rs12632942 in SCN10A exon and oxaliplatin-induced peripheral neuropathy(OXLIPN)in colorectal cancer(CRC)patients receiving chemotherapy.Methods:A total of 319 cases of blood samples from CRC patients receiving chemotherapy regimen with Oxaliplatin(OXL)were collected from the Second Affiliated Hospital of Guangzhou Medical University,the Second Affiliated Hospital of Nanchang University,and Guangzhou Baiyun District Hospital of Chinese Medicine during January 2011 and June 2013.DNA was routinely extracted,and PCR amplification was performed to analyze the genotype of rs12632942;and OXLIPN of patients was also evaluated.The association between rs12632942 genotype and OXLIPN was analyzed byχ~2 test and multivariate logistic regression model.Results:The genotypes of rs12632942 of 319 CRC patients:AA of 134 cases,AG of 156 cases and GG of 29 cases;and the genotype distribution of rs12632942 was in accordance with Hardy-Weinberg equiliberum(P>0.05).χ~2 test showed that rs12632942 AG+GG genotype was associated withⅡ-Ⅳdegree OXLIPN(P<0.01).Multivariate logistic regression model showed that rs12632942 AG+GG genotype was an independent risk factor forⅡ-Ⅳdegree OXLIPN(OR=2.044;95%CI=1.231-3.392;P<0.01).Conclusion:Colorectal cancer patients with SCN10A exon polymorphism rs12632942 AG+GG genotype were susceptible toⅡ-Ⅳdegree OXLIPN.
作者
孔连广
彭俊玲
郑祥珍
苏芳
魏宜胜
张啸
洪楚原
翁洁玲
KONG Lianguang;PENG Junling;ZHENG Xiangzhen;SU Fang;WEI Yisheng;ZHANG Xiao;HONG Chuyuan;WENG Jieling(Department of General Surgery,Guangzhou Baiyun District Hospital of Chinese Medicine,Guangzhou 510470,Guangdong,China;Department of Molecular Diagnostics,Sun Yat-Sen University Cancer Center,Guangzhou 510060,Guangdong,China;Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation,Sun Yat-Sen Memorial Hospital,SunYat-Sen University,Guangzhou 510120,Guangdong,China;Laboratory of Surgery,Department of Gastrointestinal Surgery,the Second Affiliated Hospital of Guangzhou Medical University,Guangzhou 510260,Guangdong,China;Department of Pathology,the Second Affiliated Hospital of Guangzhou Medical University,Guangzhou 510260,Guangdong,China)
出处
《中国肿瘤生物治疗杂志》
CAS
CSCD
北大核心
2019年第7期788-792,共5页
Chinese Journal of Cancer Biotherapy
基金
广州市科技计划资助项目(No.201804010072)
广东省公益研究与能力建设专项资助项目(No.2014A020212333)
广东省恶性肿瘤表观遗传与基因调控重点实验室开放基金资助(No.2017B030314026)~~